KLRK1 and plasma cell myeloma: NKG2D-expressing CAR-T cells and NK cells showed effective and persistent antitumor activity against multiple myeloma [30], osteosarcoma [14], ovarian [31], and Ewing sarcoma [32] in the mouse model.